You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大華繼顯降藥明康德(02359.HK)目標價至28元 年度業績略遜預期
大華繼顯發表研究報告指,藥明康德(02359.HK)2023年的營業收入和調整後淨利潤,分別按年增長2.5%及15.5%,相關表現略低於該行預期。另外,由於美國《生物安全法案》草案可能對公司服務需求帶來相當大的不確定性,管理層對2024年的收入指引相對較為保守,料為383億元人民幣至405億元人民幣。 因應以上情況,大華繼顯將藥明康德2024年至2026年的收入增長預測,由8.3%下調至3.3%,以反映公司業績表現較低的增長可見度。同時將藥明康德的目標價由40港元下調至28港元,維持「沽售」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account